Razaxaban hydrochloride
≥98%
- Product Code: 55236
CAS:
405940-76-3
| Molecular Weight: | 564.92 g./mol | Molecular Formula: | C₂₄H₂₁ClF₄N₈O₂ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | Room temperature, dry, sealed |
Product Description:
Razaxaban hydrochloride is primarily investigated for its anticoagulant properties, making it a potential candidate for preventing and treating thromboembolic disorders. It works by inhibiting Factor Xa, a key enzyme in the blood coagulation cascade, thereby reducing the risk of blood clot formation. This mechanism is particularly useful in conditions such as deep vein thrombosis, pulmonary embolism, and stroke prevention in patients with atrial fibrillation. Its application is also being explored in post-surgical settings to minimize the risk of clot-related complications. Additionally, it may offer advantages in patients requiring long-term anticoagulation therapy due to its targeted action and potential for reduced bleeding risks compared to traditional anticoagulants. Research continues to evaluate its efficacy, safety, and potential use in various cardiovascular and thrombotic conditions.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | ฿9,900.00 |
+
-
|
| 0.025 | 10-20 days | ฿37,800.00 |
+
-
|
Razaxaban hydrochloride
Razaxaban hydrochloride is primarily investigated for its anticoagulant properties, making it a potential candidate for preventing and treating thromboembolic disorders. It works by inhibiting Factor Xa, a key enzyme in the blood coagulation cascade, thereby reducing the risk of blood clot formation. This mechanism is particularly useful in conditions such as deep vein thrombosis, pulmonary embolism, and stroke prevention in patients with atrial fibrillation. Its application is also being explored in post-surgical settings to minimize the risk of clot-related complications. Additionally, it may offer advantages in patients requiring long-term anticoagulation therapy due to its targeted action and potential for reduced bleeding risks compared to traditional anticoagulants. Research continues to evaluate its efficacy, safety, and potential use in various cardiovascular and thrombotic conditions.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :